Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04663997
Title 177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer
Recruitment Recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors Canadian Cancer Trials Group
Indications

prostate cancer

Therapies

Docetaxel

lutetium Lu 177 vipivotide tetraxetan

Age Groups: adult | senior
Covered Countries CAN


No variant requirements are available.